Japanese Earnings Roundup: Eisai's Accelerated Perampanel Development Hits The Brakes; Takeda Averts Actos Setbacks For Now
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A busy Friday of quarterly earnings presentations gave a first glimpse of the full impact of the March 11 earthquake and tsunami in Northern Japan. Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co., Ltd., Daiichi Sankyo Co. Ltd, Mitsubishi Tanabe Pharma Corp. and Dainippon Sumitomo Pharma Co. Ltd. all reported July 29 earnings for the first full quarter since the earthquake, but perhaps the biggest news of the day was an announcement from Eisai Co. Ltd. on a setback to what had been an ambitious drive for a key drug's approval
You may also be interested in...
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule